Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global RAS-acting Agents Market

4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global RAS-acting Agents Market Analysis and Forecast, 2017–2031

5. Key Insights
    5.1. Technological Advancements
    5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.3. Key Industry Events
    5.4. COVID-19 Impact Analysis

6. Global RAS-acting Agents Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017–2031
        6.3.1. ACE inhibitors
        6.3.2. Angiotensin II Receptor Blockers (ARBs)
        6.3.3. Renin Inhibitors
        6.3.4. Aldosterone Antagonists
        6.3.5. Others (diuretics)
    6.4. Market Attractiveness Analysis, by Drug Class

7. Global RAS-acting Agents Market Analysis and Forecast, by Indication
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Indication, 2017–2031
        7.3.1. Hypertension
        7.3.2. Heart Failure
        7.3.3. Chronic Kidney Disease
        7.3.4. Diabetic Nephropathy
        7.3.5. Coronary Artery Disease
    7.4. Market Attractiveness Analysis, by Indication

8. Global RAS-acting Agents Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global RAS-acting Agents Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region

10. North America RAS-acting Agents Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017–2031
        10.2.1. ACE inhibitors
        10.2.2. Angiotensin II Receptor Blockers (ARBs)
        10.2.3. Renin Inhibitors
        10.2.4. Aldosterone Antagonists
        10.2.5. Others (diuretics)
    10.3. Market Value Forecast, by Indication, 2017–2031
        10.3.1. Hypertension
        10.3.2. Heart Failure
        10.3.3. Chronic Kidney Disease
        10.3.4. Diabetic Nephropathy
        10.3.5. Coronary Artery Disease
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Class
        10.6.2. By Indication
        10.6.3. By Distribution Channel
        10.6.4. By Country

11. Europe RAS-acting Agents Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017–2031
        11.2.1. ACE inhibitors
        11.2.2. Angiotensin II Receptor Blockers (ARBs)
        11.2.3. Renin Inhibitors
        11.2.4. Aldosterone Antagonists
        11.2.5. Others (diuretics)
    11.3. Market Value Forecast, by Indication, 2017–2031
        11.3.1. Hypertension
        11.3.2. Heart Failure
        11.3.3. Chronic Kidney Disease
        11.3.4. Diabetic Nephropathy
        11.3.5. Coronary Artery Disease
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Class
        11.6.2. By Indication
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region

12. Asia Pacific RAS-acting Agents Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017–2031
        12.2.1. ACE inhibitors
        12.2.2. Angiotensin II Receptor Blockers (ARBs)
        12.2.3. Renin Inhibitors
        12.2.4. Aldosterone Antagonists
        12.2.5. Others (diuretics)
    12.3. Market Value Forecast, by Indication, 2017–2031
        12.3.1. Hypertension
        12.3.2. Heart Failure
        12.3.3. Chronic Kidney Disease
        12.3.4. Diabetic Nephropathy
        12.3.5. Coronary Artery Disease
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Class
        12.6.2. By Indication
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America (LATAM) RAS-acting Agents Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017–2031
        13.2.1. ACE inhibitors
        13.2.2. Angiotensin II Receptor Blockers (ARBs)
        13.2.3. Renin Inhibitors
        13.2.4. Aldosterone Antagonists
        13.2.5. Others (diuretics)
    13.3. Market Value Forecast, by Indication, 2017–2031
        13.3.1. Hypertension
        13.3.2. Heart Failure
        13.3.3. Chronic Kidney Disease
        13.3.4. Diabetic Nephropathy
        13.3.5. Coronary Artery Disease
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of LATAM
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Class
        13.6.2. By Indication
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa RAS-acting Agents Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017–2031
        14.2.1. ACE inhibitors
        14.2.2. Angiotensin II Receptor Blockers (ARBs)
        14.2.3. Renin Inhibitors
        14.2.4. Aldosterone Antagonists
        14.2.5. Others (diuretics)
    14.3. Market Value Forecast, by Indication, 2017–2031
        14.3.1. Hypertension
        14.3.2. Heart Failure
        14.3.3. Chronic Kidney Disease
        14.3.4. Diabetic Nephropathy
        14.3.5. Coronary Artery Disease
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Hospital Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Class
        14.6.2. By Indication
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. Novartis AG
            15.3.1.1. Company Overview
            15.3.1.2. Drug Class Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Pfizer, Inc.
            15.3.2.1. Company Overview
            15.3.2.2. Drug Class Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. AstraZeneca plc
            15.3.3.1. Company Overview
            15.3.3.2. Drug Class Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Merck & Co., Inc.
            15.3.4.1. Company Overview
            15.3.4.2. Drug Class Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Sanofi S.A.
            15.3.5.1. Company Overview
            15.3.5.2. Drug Class Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Bristol-Myers Squibb Company
            15.3.6.1. Company Overview
            15.3.6.2. Drug Class Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Daiichi Sankyo Company, Limited
            15.3.7.1. Company Overview
            15.3.7.2. Drug Class Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Takeda Pharmaceutical Company Limited
            15.3.8.1. Company Overview
            15.3.8.2. Drug Class Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Boehringer Ingelheim GmbH
            15.3.9.1. Company Overview
            15.3.9.2. Drug Class Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Johnson & Johnson
            15.3.10.1. Company Overview
            15.3.10.2. Drug Class Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global RAS-acting Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global RAS-acting Agents Market Revenue (US$ Mn), by Drug Class, 2022

Figure 03: Global RAS-acting Agents Market Value Share, by Drug Class, 2022

Figure 04: Global RAS-acting Agents Market Revenue (US$ Mn), by Indication, 2022

Figure 05: Global RAS-acting Agents Market Value Share, by Indication, 2022

Figure 06: Global RAS-acting Agents Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global RAS-acting Agents Market Value Share, by Distribution Channel, 2022

Figure 08: Global RAS-acting Agents Market Value Share, by Region, 2022

Figure 09: Global RAS-acting Agents Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 11: Global RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 12: Global RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 13: Global RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023-2031

Figure 14: Global RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 15: Global RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 16: Global RAS-acting Agents Market Value Share Analysis, by Region, 2022 and 2031

Figure 17: Global RAS-acting Agents Market Attractiveness Analysis, by Region, 2023-2031

Figure 18: North America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America RAS-acting Agents Market Attractiveness Analysis, by Country, 2017–2031

Figure 20: North America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 21: North America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 22: North America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 23: North America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 24: North America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 25: North America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 26: North America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 27: Europe RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 29: Europe RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 31: Europe RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 32: Europe RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 33: Europe RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 34: Europe RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 35: Europe RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 38: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 39: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 40: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 41: Asia Pacific RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 42: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 43: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 44: Asia Pacific RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America RAS-acting Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 47: Latin America RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 48: Latin America RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 49: Latin America RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 50: Latin America RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 51: Latin America RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 52: Latin America RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 53: Latin America RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 56: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 57: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 58: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Indication, 2022 and 2031

Figure 59: Middle East & Africa RAS-acting Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 60: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 61: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Indication, 2023–2031

Figure 62: Middle East & Africa RAS-acting Agents Market Attractiveness Analysis, by Distribution Channel, 2023–2031

List of Tables

List of Tables

Table 01: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 03: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031